2023
Risk of Subsequent Neoplasms in Childhood Cancer Survivors After Radiation Therapy: A PENTEC Comprehensive Review
Casey D, Vogelius I, Brodin N, Roberts K, Avanzo M, Moni J, Owens C, Ronckers C, Constine L, Bentzen S, Olch A. Risk of Subsequent Neoplasms in Childhood Cancer Survivors After Radiation Therapy: A PENTEC Comprehensive Review. International Journal Of Radiation Oncology • Biology • Physics 2023, 119: 640-654. PMID: 37777927, DOI: 10.1016/j.ijrobp.2023.07.025.Peer-Reviewed Original ResearchChildhood cancer survivorsCancer survivorsRadiation therapySubsequent meningiomaLung cancerCNS neoplasmsSubsequent neoplasmsSubsequent sarcomaRT dosePrimary diagnosisHigh riskPediatric Normal Tissue EffectsRadiation dose-response relationshipSubsequent lung cancerPrior radiation therapyTreatment-related factorsExcess absolute riskPrimary cancer diagnosisERR/GyNormal tissue effectsSpecific chemotherapeutic agentsDose-response relationshipHigh-dose volumeSignificant contributory roleERR/
2021
A phase I/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.
Shaya J, Xie W, Saraiya B, Parikh M, Folefac E, Olson A, Choudhury A, Einstein D, Heath E, Parikh R, Kunos C, Ivy S, LoRusso P, Kurzrock R, Shapiro G, McKay R. A phase I/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress. Journal Of Clinical Oncology 2021, 39: tps182-tps182. DOI: 10.1200/jco.2021.39.6_suppl.tps182.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerPhase 2 componentCastration-resistant prostate cancerPhase 1 componentBone metastasesRadium-223PARP inhibitorsPrimary endpointOverall survivalProstate cancerPhase I/II studyRadiographic progression-free survivalFirst skeletal eventKey exclusion criteriaMore bone metastasesNon-bone metastasisPhase 2 doseStratification of responsePhase 1/2 studyPrior radiation therapyPhase 1/2 trialProgression-free survivalDose-escalation designTumor immune microenvironmentPlasma cell-free DNA
2020
Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers
Fan D, Kang JJ, Fan M, Wang H, Lee A, Yu Y, Chen L, Tsai C, McBride SM, Riaz N, Gelblum DY, Neal BP, Fetten J, Dunn LA, Michel LS, Boyle JO, Cohen MA, Roman BR, Ganly I, Singh B, Wong RJ, Sherman EJ, Lee NY. Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers. Oral Oncology 2020, 104: 104641. PMID: 32182548, PMCID: PMC8480112, DOI: 10.1016/j.oraloncology.2020.104641.Peer-Reviewed Original ResearchConceptsLocoregional progression-free survivalQuad Shot regimenOverall survivalPalliative responseRadiation therapyNeck cancerMedian locoregional progression-free survivalGrade 3 toxicity ratesOverall palliative response rateMedian overall survivalPalliative response ratePrior radiation therapyProgression-free survivalRadiation-related toxicityFree survivalPalliative therapyMedian ageLocal therapyPalliative optionSurvival improvementProton radiation therapyToxicity ratesTumor reductionIrradiated headLocal treatment
2018
Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience
Sawas A, Kuruvilla J, Lue J, Deng C, Amengual J, Montanari F, Savage K, Elgedawe H, Villa D, Crump M, Connors J, O'Connor O. Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience. Blood 2018, 132: 2907. DOI: 10.1182/blood-2018-99-117251.Peer-Reviewed Original ResearchAutologous stem cell transplantProgression-free survivalRefractory Hodgkin lymphomaComplete response rateDose limiting toxicitiesHigh-dose chemotherapyOverall response rateHodgkin's lymphomaBrentuximab vedotinOverall survivalDay 1Partial responseMedian numberDose levelsPrior autologous stem cell transplantResponse rateAutologous stem cell transplantationSeattle GeneticsPhase II dosePhysician's choice chemotherapyPrior radiation therapyPrior systemic therapyLong-term respondersSubset of patientsEvidence of relapse
2017
Nivolumab combined with hypofractionated stereotactic irradiation (HFSRT) for patients with recurrent high grade gliomas: A phase I trial (NCT02829931).
Sahebjam S, Forsyth P, Arrington J, Tran N, Jaglal M, Mokhtari S, Long W, Macaulay R, Wicklund M, Drury-Sibiga A, Gatewood T, Robinson T, Raval R, Yu M. Nivolumab combined with hypofractionated stereotactic irradiation (HFSRT) for patients with recurrent high grade gliomas: A phase I trial (NCT02829931). Journal Of Clinical Oncology 2017, 35: tps2084-tps2084. DOI: 10.1200/jco.2017.35.15_suppl.tps2084.Peer-Reviewed Original ResearchHigh-grade gliomasPhase I trialGrade gliomasI trialPD-1PD-L1Grade IIIAnti-PD-1/PD-L1 blockadePD-1/PD-L1 blockadeRecurrent high-grade gliomaOngoing phase I trialDose-expansion cohortsPD-L1 blockadePrior radiation therapyTolerability of nivolumabGroup of patientsImmune checkpoint pathwaysLimited treatment optionsPreliminary antitumor activityOrthotopic murine modelLong-term survivalPrimary study objectiveIgG4 monoclonal antibodyNivolumab monotherapySafety cohort
2016
“Breast in a Day”
Choi M, Frey JD, Alperovich M, Levine JP, Karp NS. “Breast in a Day”. Plastic & Reconstructive Surgery 2016, 138: 184e-191e. PMID: 27465178, DOI: 10.1097/prs.0000000000002333.Peer-Reviewed Original ResearchConceptsPermanent implant reconstructionNipple-sparing mastectomyMastectomy flap necrosisImplant reconstructionAcellular dermal matrixComplication rateFlap necrosisMajor mastectomy flap necrosisMinor mastectomy flap necrosisDermal matrixImplant sizeCLINICAL QUESTION/LEVELPercent of reconstructionsCommon major complicationPrior radiation therapyGreater complication rateLow complication rateNipple-sparing mastectomiesBody mass indexCommon minor complicationAverage implant sizeMajority of implantsOverall complicationsNipple necrosisMinor complications
2015
Gamma Knife radiosurgery for posterior fossa meningiomas: a multicenter study.
Sheehan JP, Starke RM, Kano H, Barnett GH, Mathieu D, Chiang V, Yu JB, Hess J, McBride HL, Honea N, Nakaji P, Lee JY, Rahmathulla G, Evanoff WA, Alonso-Basanta M, Lunsford LD. Gamma Knife radiosurgery for posterior fossa meningiomas: a multicenter study. Journal Of Neurosurgery 2015, 122: 1479-89. PMID: 25859812, DOI: 10.3171/2014.10.jns14139.Peer-Reviewed Original ResearchConceptsPosterior fossa meningiomasTumor volumeStereotactic radiosurgeryTumor controlRadiation therapyNorth American Gamma Knife ConsortiumTumor progressionActuarial tumor controlMedian margin doseMedian patient agePrior radiation therapyMean tumor volumeGamma knife radiosurgerySmaller tumor volumeNeurological preservationMargin dosePrior resectionClinical stabilityNeurological declinePatient ageShunt placementRecurrent tumorsClinical entityMulticenter studyKnife radiosurgeryPretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT.
Alagappan M, Pollom E, von Eyben R, Kunz P, Fisher G, Ford J, Poultsides G, Visser B, Norton J, Kamaya A, Columbo L, Koong A, Chang D. Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT. Journal Of Clinical Oncology 2015, 33: 433-433. DOI: 10.1200/jco.2015.33.3_suppl.433.Peer-Reviewed Original ResearchUnresectable pancreatic adenocarcinomaStereotactic body radiotherapyHigh NL ratioPrior radiation therapyOverall survivalBlood cell countStart of treatmentPancreatic adenocarcinomaTumor marker valuesNL ratioResectable diseaseEntire cohortCA 19Univariate analysisRadiation therapyCell countWhite blood cell countTumor marker CA 19Marker valuesLab valuesBorderline resectable diseasePre-treatment CEAMedian overall survivalAbsolute lymphocyte countAbsolute neutrophil count
2014
Gamma Knife radiosurgery for sellar and parasellar meningiomas: a multicenter study.
Sheehan JP, Starke RM, Kano H, Kaufmann AM, Mathieu D, Zeiler FA, West M, Chao ST, Varma G, Chiang VL, Yu JB, McBride HL, Nakaji P, Youssef E, Honea N, Rush S, Kondziolka D, Lee JY, Bailey RL, Kunwar S, Petti P, Lunsford LD. Gamma Knife radiosurgery for sellar and parasellar meningiomas: a multicenter study. Journal Of Neurosurgery 2014, 120: 1268-77. PMID: 24678777, DOI: 10.3171/2014.2.jns13139.Peer-Reviewed Original ResearchConceptsGamma knife radiosurgeryPrior radiation therapyParasellar meningiomasSellar meningiomasKnife radiosurgeryRadiation therapyPrior surgeryMulticenter studyTumor controlTumor volumeActuarial progression-free survival ratesNorth American Gamma Knife ConsortiumTumor progressionProgression-free survival ratesCox multivariate regression analysisTumor margin doseNew neurological deficitsCranial nerve deficitsPrimary treatment modalityKaplan-Meier analysisCranial nerves VLarger tumor volumeConventional radiation therapyMonths of imagingMultivariate regression analysis
2013
Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study.
Sheehan JP, Starke RM, Mathieu D, Young B, Sneed PK, Chiang VL, Lee JY, Kano H, Park KJ, Niranjan A, Kondziolka D, Barnett GH, Rush S, Golfinos JG, Lunsford LD. Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. Journal Of Neurosurgery 2013, 119: 446-56. PMID: 23621595, DOI: 10.3171/2013.3.jns12766.Peer-Reviewed Original ResearchConceptsPrior radiation therapyPituitary adenomasTumor controlNonfunctional pituitary adenomasNerve dysfunctionRadiation therapyNorth American Gamma Knife ConsortiumActuarial tumor controlDegree of hypopituitarismMulticenter patient populationTime of radiosurgeryCranial nerve deficitsPercent of patientsCranial nerve functionOptic nerve dysfunctionCranial nerve dysfunctionGamma Knife surgeryManagement of patientsOverall tumor controlGamma knife radiosurgeryExternal beam radiotherapyProgressive cranial nerve deficitsCommon intracranial neoplasmsDelayed hypopituitarismMargin doses
2006
Quality of life (QOL) companion to CALGB 9840: A phase III study of paclitaxel (P) via weekly 1 hour (hr) versus standard 3 hour infusion every 3 weeks with trastuzumab in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast cancer
Naughton M, Gu L, Wang X, Seidman A, Winer E, Kornblith A. Quality of life (QOL) companion to CALGB 9840: A phase III study of paclitaxel (P) via weekly 1 hour (hr) versus standard 3 hour infusion every 3 weeks with trastuzumab in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast cancer. Journal Of Clinical Oncology 2006, 24: 674-674. DOI: 10.1200/jco.2006.24.18_suppl.674.Peer-Reviewed Original ResearchNegative patientsQOL differencesGreater efficacyMain trial resultsPrior radiation therapyMetastatic breast cancerPhase III studyTreatment of patientsMain outcome measuresEORTC-C30Prior chemotherapyBreast symptomsIII studyPerformance statusPatient ageHour infusionTreatment armsBreast moduleGlobal QoLCancer symptomsBreast cancerClinical dataQoL dataOutcome measuresRadiation therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply